BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J 2012;42:997-1007. [PMID: 24020339 DOI: 10.1111/j.1445-5994.2012.02794.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Guan S, Tang Z, Fang X, Wu X, Liu H, Wang C, Hou C. Prevalence of hyperuricemia among Beijing post-menopausal women in 10 years. Arch Gerontol Geriatr 2016;64:162-6. [PMID: 26906723 DOI: 10.1016/j.archger.2016.02.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
2 Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum 2021;51:121-8. [PMID: 33360648 DOI: 10.1016/j.semarthrit.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Murota I, Taguchi S, Sato N, Park EY, Nakamura Y, Sato K. Identification of Antihyperuricemic Peptides in the Proteolytic Digest of Shark Cartilage Water Extract Using in Vivo Activity-Guided Fractionation. J Agric Food Chem 2014;62:2392-7. [DOI: 10.1021/jf405504u] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
4 Li Y, Shen Z, Zhu B, Zhang H, Zhang X, Ding X. Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis. Glob Health Action 2021;14:1874652. [PMID: 33475474 DOI: 10.1080/16549716.2021.1874652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Barrett C, Bird P, Major G, Romas E, Portek I, Taylor A, Zochling J; Australian and New Zealand 3e Group. Australian and New Zealand national evidence-based recommendations for the investigation and follow-up of undifferentiated peripheral inflammatory arthritis: an integration of systematic literature research and rheumatological expert opinion. Int J Rheum Dis 2013;16:637-51. [PMID: 24131599 DOI: 10.1111/1756-185X.12189] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Bardin T, Voshaar MA, van de Laar MA. The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis. Joint Bone Spine 2015;82 Suppl 1:eS2-8. [PMID: 26717799 DOI: 10.1016/S1297-319X(15)30002-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Mehmood A, Zhao L, Wang C, Nadeem M, Raza A, Ali N, Shah AA. Management of hyperuricemia through dietary polyphenols as a natural medicament: A comprehensive review. Crit Rev Food Sci Nutr 2019;59:1433-55. [PMID: 29278921 DOI: 10.1080/10408398.2017.1412939] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
8 Wändell P, Carlsson AC, Ljunggren G. Gout and its comorbidities in the total population of Stockholm. Preventive Medicine 2015;81:387-91. [DOI: 10.1016/j.ypmed.2015.10.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
9 Ramasamy SN, Korb-wells CS, Kannangara DRW, Smith MWH, Wang N, Roberts DM, Graham GG, Williams KM, Day RO. Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012. Drug Saf 2013;36:953-80. [DOI: 10.1007/s40264-013-0084-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 11.3] [Reference Citation Analysis]
10 Zhou Y, Zhang M, He D, Hu X, Xiong H, Wu J, Zhu B, Zhang J. Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes. Sci Rep 2016;7:20136. [PMID: 26823332 DOI: 10.1038/srep20136] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
11 Ao J, Goldblatt F, Casson RJ. Review of the ophthalmic manifestations of gout and uric acid crystal deposition: Review of the ophthalmic manifestations of gout. Clinical & Experimental Ophthalmology 2017;45:73-80. [DOI: 10.1111/ceo.12749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Jeyaruban A, Soden M, Larkins S. Prevalence of comorbidities and management of gout in a tropical city in Australia. Rheumatol Int 2016;36:1753-8. [DOI: 10.1007/s00296-016-3580-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J, Keown S, Herbison P. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int 2014;34:963-70. [DOI: 10.1007/s00296-013-2935-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
14 Waldman B, Ansquer J, Sullivan DR, Jenkins AJ, Mcgill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. The Lancet Diabetes & Endocrinology 2018;6:310-8. [DOI: 10.1016/s2213-8587(18)30029-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
15 Singh JA, Cleveland JD. Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data. RMD Open. 2018;4:e000712. [PMID: 30018808 DOI: 10.1136/rmdopen-2018-000712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Cavagna L, Taylor WJ. The emerging role of biotechnological drugs in the treatment of gout. Biomed Res Int 2014;2014:264859. [PMID: 24839602 DOI: 10.1155/2014/264859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang D, Yu Y, Chen Y, Yang N, Zhang H, Wang C, Wang Q, Wang X, Zeng X, Estill J. Assessing the Quality of Global Clinical Practice Guidelines on Gout Using AGREE II Instrument. J Clin Rheumatol 2020;26:54-9. [PMID: 32073515 DOI: 10.1097/RHU.0000000000000921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. J Rheumatol 2015;42:1702-7. [DOI: 10.3899/jrheum.150310] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
19 Robinson PC, Taylor WJ, Merriman TR. Author reply. Intern Med J 2013;43:466-466. [DOI: 10.1111/imj.12094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Counsell AB, Nguyen AD, Baysari MT, Kannangara DRW, McLachlan AJ, Day RO. Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Fam Pract 2018;19:54. [PMID: 29743018 DOI: 10.1186/s12875-018-0744-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
21 Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO. An audit of a therapeutic drug monitoring service for allopurinol therapy. Ther Drug Monit 2013;35:863-6. [PMID: 24263644 DOI: 10.1097/FTD.0b013e318299920a] [Reference Citation Analysis]
22 Robinson PC, Horsburgh S. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 2014;78:245-51. [PMID: 24880206 DOI: 10.1016/j.maturitas.2014.05.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
23 Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649-662. [PMID: 26150127 DOI: 10.1038/nrrheum.2015.91] [Cited by in Crossref: 520] [Cited by in F6Publishing: 419] [Article Influence: 74.3] [Reference Citation Analysis]
24 Coulshed A, Nguyen AD, Stocker SL, Day RO. Australian patient perspectives on the impact of gout. Int J Rheum Dis 2020;23:1372-8. [DOI: 10.1111/1756-185x.13934] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Tanner C, Boocock J, Stahl EA, Dobbyn A, Mandal AK, Cadzow M, Phipps-Green AJ, Topless RK, Hindmarsh JH, Stamp LK, Dalbeth N, Choi HK, Mount DB, Merriman TR. Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. Arthritis Rheumatol 2017;69:1461-9. [PMID: 28371506 DOI: 10.1002/art.40110] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
26 Robinson PC, Kempe S, Tebbutt I, Roberts L. Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site. Int J Rheum Dis 2017;20:779-84. [PMID: 27455925 DOI: 10.1111/1756-185X.12941] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
27 Nguyen AD, Lind KE, Day RO, Georgiou A, Westbrook JI. A profile of health status and demographics of aged care facility residents with gout. Australas J Ageing 2020;39. [DOI: 10.1111/ajag.12716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Desai RJ, Franklin JM, Spoendlin-Allen J, Solomon DH, Danaei G, Kim SC. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One. 2018;13:e0193622. [PMID: 29489919 DOI: 10.1371/journal.pone.0193622] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
29 Molla MD, Bekele A, Melka DS, Teklemariam MD, Challa F, Ayelign B, Shibabaw T, Akalu Y, Geto Z. Hyperuricemia and Its Associated Factors Among Adult Staff Members of the Ethiopian Public Health Institute, Ethiopia. Int J Gen Med 2021;14:1437-47. [PMID: 33907448 DOI: 10.2147/IJGM.S308158] [Reference Citation Analysis]
30 Li Z, Guo X, Liu Y, Chang Y, Sun Y, Zhu G, Abraham MR. The Relation of Moderate Alcohol Consumption to Hyperuricemia in a Rural General Population. Int J Environ Res Public Health. 2016;13:pii: E732. [PMID: 27447659 DOI: 10.3390/ijerph13070732] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Lu J, Dalbeth N, Yin H, Li C, Merriman TR, Wei WH. Mouse models for human hyperuricaemia: a critical review. Nat Rev Rheumatol 2019;15:413-26. [PMID: 31118497 DOI: 10.1038/s41584-019-0222-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
32 Rick J, Tsai MC, Hwang BJ. Biosensors Incorporating Bimetallic Nanoparticles. Nanomaterials (Basel) 2015;6:E5. [PMID: 28344262 DOI: 10.3390/nano6010005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 5.1] [Reference Citation Analysis]
33 Lu X, Li X, Zhao Y, Zheng Z, Guan S, Chan P. Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing. Int J Rheum Dis 2014;17:400-7. [DOI: 10.1111/1756-185x.12156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
34 Vaccher S, Kannangara DR, Baysari MT, Reath J, Zwar N, Williams KM, Day RO. Barriers to Care in Gout: From Prescriber to Patient. J Rheumatol 2016;43:144-9. [PMID: 26568590 DOI: 10.3899/jrheum.150607] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
35 Bavanendrakumar M, Robinson PC. Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. Intern Med J 2020;50:337-41. [PMID: 31386267 DOI: 10.1111/imj.14445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
36 Koguchi T, Tadokoro T. Beneficial Effect of Dietary Fiber on Hyperuricemia in Rats and Humans: A Review. Int J Vitam Nutr Res 2019;89:89-108. [PMID: 30789803 DOI: 10.1024/0300-9831/a000548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Madala ND, Dubula T, Assounga AGH, Naicker S. Association of Kidney Function and Waist Circumference with Uric Acid Levels in South Africans. Metab Syndr Relat Disord 2017;15:500-6. [PMID: 29154722 DOI: 10.1089/met.2017.0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Liu R, Han C, Wu D, Xia X, Gu J, Guan H, Shan Z, Teng W. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int 2015;2015:762820. [PMID: 26640795 DOI: 10.1155/2015/762820] [Cited by in Crossref: 133] [Cited by in F6Publishing: 164] [Article Influence: 19.0] [Reference Citation Analysis]
39 Ting K, Gill TK, Keen H, Tucker GR, Hill CL. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J 2016;46:566-73. [PMID: 26765205 DOI: 10.1111/imj.13006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
40 Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol 2017;83:2015-26. [PMID: 28417592 DOI: 10.1111/bcp.13307] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
41 Dong Z, Guo S, Yang Y, Wu J, Guan M, Zou H, Jin L, Wang J. Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis. Int J Rheum Dis 2015;18:382-91. [PMID: 25639607 DOI: 10.1111/1756-185X.12519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
42 Tang H, Xu G, Zheng Q, Cheng Y, Zheng H, Li J, Yin Z, Liang F, Chen J. Treatment for acute flares of gout: A protocol for systematic review. Medicine (Baltimore) 2020;99:e19668. [PMID: 32243400 DOI: 10.1097/MD.0000000000019668] [Reference Citation Analysis]
43 Bardin T, Bouée S, Clerson P, Chalès G, Flipo RM, Lioté F, Perez V, Poiraud T, Schaeverbeke T, Richette P. Prevalence of Gout in the Adult Population of France. Arthritis Care Res (Hoboken) 2016;68:261-6. [PMID: 26234279 DOI: 10.1002/acr.22660] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
44 Nathan N, Nguyen AD, Stocker S, Laba TL, Baysari MT, Day RO. Out-of-pocket spending among a cohort of Australians living with gout. Int J Rheum Dis 2021;24:327-34. [PMID: 32975889 DOI: 10.1111/1756-185X.13979] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Rheumatology AF, Rheumatologist PK; clinical pharmacology registrar., clinical pharmacologist. The management of gout. Aust Prescr 2016;39:119-22. [PMID: 27756973 DOI: 10.18773/austprescr.2016.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
46 Zhang Y, Yang Y, Xue L, Wen J, Bo L, Tang M, Yang R, Yan D, Liu Z. Clinical characteristics of patients under 40 years old with early-onset hyperuricaemia: a retrospective monocentric study in China. BMJ Open 2019;9:e025528. [PMID: 31462461 DOI: 10.1136/bmjopen-2018-025528] [Reference Citation Analysis]
47 Douglas WA. Gouty arthritis in Australian Aborigines. Intern Med J 2013;43:465-465. [DOI: 10.1111/imj.12107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Day RO, Lau W, Stocker SL, Aung E, Coleshill MJ, Schulz M, Bechara J, Carland JE, Graham GG, Williams KM, Mclachlan AJ. Management of gout in older people. J Pharm Pract Res 2019;49:90-7. [DOI: 10.1002/jppr.1511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Head GA. Cardiovascular and metabolic consequences of obesity. Front Physiol 2015;6:32. [PMID: 25713539 DOI: 10.3389/fphys.2015.00032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
50 Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, Vangjeli C. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne) 2018;5:160. [PMID: 29904633 DOI: 10.3389/fmed.2018.00160] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 16.5] [Reference Citation Analysis]
51 Wijnands JM, Viechtbauer W, Thevissen K, Arts IC, Dagnelie PC, Stehouwer CD, van der Linden S, Boonen A. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol 2015;30:19-33. [PMID: 25064615 DOI: 10.1007/s10654-014-9927-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
52 Helget LN, England BR, Roul P, Sayles H, Petro AD, Michaud K, Mikuls TR. Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. Arthritis Care Res 2021;73:1363-71. [DOI: 10.1002/acr.24339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
53 Graf SW, Whittle SL, Wechalekar MD, Moi JH, Barrett C, Hill CL, Littlejohn G, Lynch N, Major G, Taylor AL, Buchbinder R, Zochling J. Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis 2015;18:341-51. [PMID: 25884565 DOI: 10.1111/1756-185X.12557] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
54 Robinson PC, Dalbeth N. Advances in pharmacotherapy for the treatment of gout. Expert Opinion on Pharmacotherapy 2014;16:533-46. [DOI: 10.1517/14656566.2015.997213] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
55 Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin GR, Dal Grande E, Gill TK, Whittle SL, Hill CL. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther 2018;20:143. [PMID: 29996922 DOI: 10.1186/s13075-018-1633-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
56 Wändell P, Andreasson A, Hagström H, Kapetanovic M, Carlsson A. The use of anthropometric measures in the prediction of incident gout: results from a Swedish community-based cohort study. Scandinavian Journal of Rheumatology 2019;48:294-9. [DOI: 10.1080/03009742.2019.1583368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Kapetanovic MC, Hameed M, Turkiewicz A, Neogi T, Saxne T, Jacobsson L, Englund M. Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. RMD Open 2016;2:e000326. [PMID: 27933209 DOI: 10.1136/rmdopen-2016-000326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
58 Safiri S, Kolahi A, Cross M, Carson‐chahhoud K, Hoy D, Almasi‐hashiani A, Sepidarkish M, Ashrafi‐asgarabad A, Moradi‐lakeh M, Mansournia MA, Kaufman JS, Collins G, Woolf AD, March L, Smith E. Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990–2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol 2020;72:1916-27. [DOI: 10.1002/art.41404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
59 Quintana R, Silvestre AM, Goñi M, García V, Mathern N, Jorfen M, Miljevic J, Dhair D, Laithe M, Conti S, Midauar F, Martin MC, Barrios MC, Nieto R, Prigione C, Sanabria A, Gervasoni V, Grabbe E, Gontero R, Peláez-Ballestas I, Pons-Estel BA. Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina. Clin Rheumatol 2016;35 Suppl 1:5-14. [PMID: 26852314 DOI: 10.1007/s10067-016-3192-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]